Navigation Links
AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
Date:5/29/2008

AMSTERDAM, May 30 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that positive interim data from its pivotal clinical trial with AMT's lead product Glybera(R) (AMT-011) were presented by the Principal Investigator, professor Daniel Gaudet, at the American Society of Gene Therapy Annual Meeting in Boston on May 29th. These data confirm the outcome of a previous study conducted in The Netherlands, demonstrating safety and efficacy of Glybera(R) for lipoprotein-lipase deficiency, a disease also known as Hyperlipoproteinemia (HPL) type I. Currently, there is no effective treatment or cure for this seriously debilitating and potentially lethal disease.

Study data

Glybera(R) is a gene therapy product that corrects the genetic defect in lipoprotein-lipase (LPL) deficient patients. LPL is normally produced in muscle tissue and is needed to break down the large fat-carrying particles that circulate in the blood after each meal. As a result, LPL-deficient patients have very high fat (triglyceride) levels in their blood which may lead to recurrent episodes of pancreatitis, insulin resistance, and fat accumulations in skin as well as liver and retina.

In the pivotal study conducted in Quebec (Canada), patients with LPL-deficiency were first enrolled in an observation study and subsequently treated in a study in which there are two different dose groups. All patients showed very high fat levels in the observation study and had experienced (recurrent) pancreatitis episodes prior to treatment. To date 6 patients have been treated with the lower dose and 7 with the higher dose.

Professor Gaudet presented data on the first 10 patients, of which 6 were in the lower dose group and 4 were in the higher dose group. The data showed that treatment was well tolerated. Fat concentrations were reduced after treatment in all patients, with one exception. In all patients
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... of the first-quarter 2010 cash dividend of $0.16 per ... 2010 to shareholders of record on January 20, 2010. ... a global manufacturer of components and systems for injectable ... closures and disposable components used in syringe, IV and ...
(Date:12/15/2009)... Ind., Dec. 15 OrthoWorx, the newly formed ... the orthopedics device sector in Kosciusko County, is working ... major cities like Chicago and Cleveland via high-speed rail. ... Warsaw, Indiana: The Orthopedics Capital of the World ... and community growth, BioCrossroads, the statewide initiative ...
(Date:12/15/2009)... -- Ever wonder what something looks like up close ... the Personal Scanning Electron Microscope (PSEM), kicked off its ... in samples to be scanned by one of their ... range of 100nm to 5mm and an imaging resolution ... focus. In addition, ASPEX will not only scan your ...
Breaking Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign 2Four Michigan Companies Receive 24200 000 From Ann Arbor SPARKs Microloan Program 14875 1Four Michigan Companies Receive 24200 000 From Ann Arbor SPARKs Microloan Program 14875 2A New Weapon In The Battle Of The Bra Bulge 6339 1A New Weapon In The Battle Of The Bra Bulge 6339 2New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 1New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 2New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 3New Genomic Test for Coronary Artery Disease Now Available at The Heart 26amp 3B Vascular Center of Arizona 6336 4
... December 10, 2007, NEW HAVEN, Conn., Dec. 6 ... that preliminary data,from its pivotal Phase II trial of ... leukemia (AML) would be presented,in a poster at the ... on Saturday, December 8, 2007., The poster presentation ...
... RDYN ) announced today that President and Chief ... and Powerful Anti-infectives,panel at the RBC Capital Markets 2007 ... am ET on Thursday, December 13, 2007 at,the Westin ... audio webcast of the panel discussion will be available ...
Other Medicine Technology:Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 2Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 3
(Date:12/15/2009)... -- The Food and Health Bureau has invited expressions ... in developing private hospitals at four sites in the ... EOI is March 31, 2010. ,, At a ... York Chow, said the promotion of private hospital development ... a major Hong Kong government policy announced by Chief ...
(Date:12/15/2009)... taxes in the healthcare bill ,, WASHINGTON, Dec. ... under the "Naughty" column on Americans for Tax Reform,s ... a brazen lie on the floor of the United States ... taxes. ,, Speaking on the U.S. Senate floor on ... I have also heard it argued that health care ...
(Date:12/15/2009)... 15 Our Lady of Lourdes Health Care ... hospitals, has agreed to pay the United States $7.95 ... the Justice Department announced today. The two hospitals are ... N.J., and Lourdes Medical Center of Burlington County (LMC) ... in a suit brought by a whistleblower, Tony Kite, ...
(Date:12/15/2009)... reproductive age were evaluated, Italian study found , , TUESDAY, ... born with cystic fibrosis decreases when screening for potential ... new study finds. , CF neonatal screening has been ... years. Since the 1990s, the area has seen a ... with CF. , Two different CF carrier detection methods ...
(Date:12/15/2009)... worse, ,we would have really been in trouble, expert ... outbreak of the pandemic H1N1 swine flu has revealed ... public health emergencies, a new report says. , The ... the Robert Wood Johnson Foundation, also finds the dire ... , "The 2009 H1N1 outbreak is the latest in ...
Breaking Medicine News(10 mins):Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 2Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 3
... the survival rate of patients infected with HIV has risen ... //India has the second highest number of patients with HIV ... of cheap generic drugs which has reduced the cost of ... ,The ART generic drug was introduced in India during ...
... one of the top organ transplant hospitals in California ... national improperly received an organ ahead of dozens of ... Times reported that officials at St. Vincent Medical Center ... allegedly falsified records of the operation on numerous occasions, ...
... an important risk factor for subsequent suicide.// ,Researchers from ... examine national patterns in the emergency department assessment and treatment ... episode of deliberate self-harm. , ... analysis of a nationally representative sample of hospital emergency department ...
... and their retirement age has revealed that workers who retire ... work on until they reach 65. //This finding disapproves the ... enjoy healthier and happier lives as a consequence. ... age than women, as were those on lower incomes compared ...
... with good health and vitality. However, just a small amount ... D. //It doesn't take much sunlight to make all the ... it takes to get a suntan. ,Recently, a study ... UV light (UVL) tanning behavior. For the study, researchers at ...
... hailed as a new 'wonder drug' after it was found to ... of the trials show that the drug can also serve as ... so far. ,In this particular study, which tracked 5,000 ... of breast cancer relapse as compared to 127 cases in patients ...
Other Medicine News:Health News:Under-Recognition Of Mental Disorders As A Cause Of Deliberate Self-Harm 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: